Trial Profile
A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2021 Results published in the Leukemia and Lymphoma
- 27 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Nov 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.